IRIDEX Corp (IRIX) stock
Close on Nov 11, 2026Market cap $11.47MP/E –Yield –
IRIDEX Corp grew revenue 3.7% to $51.57M over the twelve months to Jul 4, 2026. Free cash flow was -$2.00M. At the latest close the market valued the company at $11.47M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 4, 2026
Valuation
- Market cap
- $11.47M
- P/E ratio
- –
- Price to sales
- 0.22
- Price to book
- 3.15
- Dividend yield
- –
- Free cash flow yield
- -17.43%
Fundamentals
- Revenue
- $51.57M
- Net income
- -$3.55M
- EPS, diluted
- -$0.20
- Free cash flow
- -$2.00M
- Book value per share
- $0.21
- Diluted shares
- 17M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $0.70
- Open
- $0.70
- Day's range
- $0.65 – $0.73
- Volume
- 75,114
- Average volume (20 days)
- 35,963
- Beta (5 years)
- 0.93
- 52-week range
- $0.61 – $1.65
- RSI (14 days)
- 38.7
- Volatility (1 year)
- 73.5%
- Relative volume
- 0.26×
- WACC
- 9.5%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRIX | S&P 500 | Difference | IRIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.6% | -2.4% | −24.2 pts | ||
| 3 months | -26.6% | -1.2% | −25.5 pts | ||
| Year to date | -42.7% | +12.3% | −55.0 pts | ||
| 1 year | -45.1% | +12.4% | −57.6 pts | ||
| 3 years | -68.6% | +78.8% | −147.4 pts | -32.0% | +21.4% |
| 5 years | -92.7% | +75.2% | −167.9 pts | -40.8% | +11.9% |
| 10 years | -95.9% | +311.1% | −407.1 pts | -27.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Iridex filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025Results
- Update
About Iridex
Electromedical & Electrotherapeutic Apparatus
IRIDEX Corporation is an ophthalmic medical technology company that develops and commercializes products and procedures for treating sight-threatening eye conditions, primarily glaucoma and retinal diseases. Its core offerings include laser consoles, consumable probes, and delivery devices powered by proprietary MicroPulse and Endpoint Management technologies, alongside continuous-wave laser modes. Key console lines include the Cyclo G6 for glaucoma, portable IQ systems and the PASCAL platform for medical retina, and OcuLight systems for surgical retina. The company also sells single-use consumable probes, such as MicroPulse P3, G-Probe, and EndoProbe handpieces, while providing repair and maintenance services. Customers are primarily ophthalmologists who use these products in hospital operating rooms, ambulatory surgical centers, offices, and clinics.
Company profile, executives and historyIridex stock: common questions
What is Iridex's stock price?
IRIX closed at $0.65 on Nov 11, 2026, down 6.73% on the day. Over the past 52 weeks it traded between $0.61 and $1.65.
What is Iridex's market cap?
Iridex was worth $11.47M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IRIX's P/E ratio?
Iridex lost money over the twelve months to Jul 4, 2026 (diluted EPS -$0.20), so it has no meaningful P/E ratio.
How much revenue does Iridex make?
Iridex reported revenue of $51.57M for the twelve months to Jul 4, 2026, up 3.7% from a year earlier.
Does Iridex pay a dividend?
No. Iridex has not paid a cash dividend over the last twelve months.
When does Iridex report earnings next?
Iridex is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has IRIX stock performed over the past year?
Including dividends, IRIX returned -45.1% over the past year, against +12.4% for the S&P 500.
How many IRIX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.94% of the float, or 1.6 days of average trading volume.
Who are Iridex's competitors?
Companies most similar to Iridex by business, industry and size include SGHT, FOCL, LNSR, ESMC, ELMD.
See a number that looks wrong?